(Q38156608)

29 August 2017

Novel immunomodulatory approaches for the management of multiple sclerosis (English)

1 reference

29 August 2017

0 references

3

1 reference

29 August 2017

O H Kantarci

1

1 reference

PubMed ID

24173041

29 August 2017

I Pirko

series ordinal

2

1 reference

PubMed ID

24173041

29 August 2017

language of work or name

English

0 references

publication date

30 October 2013

1 reference

Clinical Pharmacology & Therapeutics

29 August 2017

1 reference

29 August 2017

95

1 reference

29 August 2017

1

1 reference

29 August 2017

32-44

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

29 August 2017

1 reference

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A clinical patho-anatomical study of clinically silent multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

The optic neuritis treatment trial: implications for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Beneficial plasma exchange response in central nervous system inflammatory demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Remyelination in the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Efficient central nervous system remyelination requires T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Interaction between oligodendroglia and immune cells: mitogenic effect of an oligodendrocyte precursor cell line on syngeneic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Growth hormone and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

The diagnosis of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Treatment of multiple sclerosis with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Younger children with MS have a distinct CSF inflammatory profile at disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Distribution of TRAP-positive cells and expression of HIF-1alpha, VEGF, and FGF-2 in the reparative reaction in patients with osteonecrosis of the femoral head

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

What have the optic neuritis treatment trial and the longitudinal optic neuritis study shown us?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Optic neuritis treatment trial. One-year follow-up results

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

The Use of Cyclophosphamide in the Treatment of Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Remyelination following viral-induced demyelination: Ferric ion?ferrocyanide staining of nodes of ranvier within the CNS

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Prognostic factors for survival in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Early prognostic factors for disability in multiple sclerosis, a European multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

1 reference

7 January 2021

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.196

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.196

1 reference

29 August 2017

1 reference

PubMed ID

24173041